about
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancerImmunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.The gene expression profile of cumulus cells reveals altered pathways in patients with endometriosisCharacterization of human γδ T lymphocytes infiltrating primary malignant melanomas.Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy.Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies.Monoclonal antibodies in gastrointestinal cancers.Targeted therapies in hepatocellular carcinoma.Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.Ramucirumab and its use in gastric cancer treatment.Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy.Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines.Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy.In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.Bortezomib: a new pro-apoptotic agent in cancer treatment.Well-being among Italian medical oncologists: an exploratory study.[Pilot study on predictive value of plasmatic levels of 9 angiogenetic biomarkers in selection of patients candidate to prostate biopsy].Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population.A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting.Primary Non-Hodgkins lymphoma of the parotid glandSignificance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective studyEffects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cellsAnalysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations
P50
Q28659468-9A832E86-D916-43D9-A450-00F6F2BCAEA2Q33357295-2454D4BB-DD78-4699-BAB7-30E7341C1CC5Q33371478-208DA179-3607-43BE-AD2A-EF83BDFF527BQ33371480-00CF7940-DD60-4F04-B393-476E78070B22Q34226377-5C3C28FE-82A6-4B4B-8B92-3ED807C7C328Q34493921-CE38DCA3-671C-40B9-8746-83E063259A95Q35771429-C59E8A66-BDFD-4ADB-80AB-EB1257CA741CQ37004739-749AF478-EE2D-4139-85F9-722C662D63BFQ37160805-BA78AD94-241F-43CB-A4CF-DC98AD1C9D32Q37645090-66FFBAA4-1948-4297-9E03-0EC6A04E340AQ37996436-2940F485-BE3F-4BA3-81BC-5E6DBAC20CD9Q38084684-436CC43D-000F-4849-9DBE-0C50AB9144EDQ38132872-169D17DB-FB3C-41E1-80C9-124A15773DBAQ38138237-6C3E10DE-9A83-4A4E-80F7-2BCD92EF7C02Q38260034-1839C739-BCAE-4C46-AB80-F5DB78AD4FBFQ38264378-524F4838-D59A-48D0-A923-75DC55C70979Q38312446-FB3FF3EA-2E90-4441-ABAB-034CC3AB394AQ39068877-E0F792BA-6B6C-43F5-A5E6-CC16E7026A84Q41857809-A497BC94-D2CE-44B7-BC4F-437549CE118AQ43057295-3992DA5B-BA13-47C0-A118-ECE86BC1019AQ43188660-1F358512-0A8A-4B0F-A16F-C824FD56C36DQ43590328-8C52C581-CFC1-425D-B48F-4CC7B5CD0C9DQ45240638-57BFF30B-5A7C-4A28-8CCE-4B877BB3829FQ46516629-D214F6EB-F849-4E85-8229-395B35D4D91BQ46616790-0EBCDADE-3206-42CD-B95C-731830465DE6Q46659743-D53B6F7D-5E4F-4C0D-BD44-89473DBF6B92Q46974222-D90905DE-64DB-4F2A-8AE7-C3A558E6D07DQ51801019-8B351661-1169-4C4C-B035-BB13A28FC0FFQ54352267-4B4F4873-2FF9-4EED-A951-7DD6E0A0BFA9Q54444545-780FA4B5-017C-48E4-96E2-E359533BAF4DQ59326262-E42232A0-CD24-4D6F-BE6D-061E9A85B1A4Q83946458-EEE116DF-7940-4E98-8E05-B432D5F69B1FQ85743841-65F78B55-F5E0-4F39-A401-41CE1F26F23DQ86703969-0E99405E-631C-4EEC-9C10-6253974A78A2
P50
description
researcher ORCID ID = 0000-0002-4717-437X
@en
wetenschapper
@nl
name
Giuseppe Cicero
@ast
Giuseppe Cicero
@en
Giuseppe Cicero
@es
Giuseppe Cicero
@nl
type
label
Giuseppe Cicero
@ast
Giuseppe Cicero
@en
Giuseppe Cicero
@es
Giuseppe Cicero
@nl
prefLabel
Giuseppe Cicero
@ast
Giuseppe Cicero
@en
Giuseppe Cicero
@es
Giuseppe Cicero
@nl
P106
P1153
57191737307
7004414279
P21
P31
P496
0000-0002-4717-437X